Over the past 2 decades, transplantation of kidneys from donation after circulatory death (DCD) donors has significantly increased.
Second, the delicate small en bloc kidney grafts may be more susceptible to surgical-mechanical injury during DCD recovery: the rapid aortic exposure, cannulation, and ensuing organ excision may place the small pediatric kidneys at higher risk for recovery-related complications. 3, 6 Third, DCD grafts in general exhibit variable in-situ flush quality, which may adversely impact preservation quality and initial reperfusion, and thus also graft thrombosis rates. Finally, a recent national registry analysis of mostly single kidney transplants from older pediatric DCD donors suggested that these grafts are at higher risk for primary nonfunction (PNF) and graft failure as compared to similar kidneys recovered from donation after brain death (DBD) donors. 7 Given the number of the preceding concerns, it is not surprising that the overall number of DCD transplants from very small pediatric en bloc donors remains extremely limited: to date, <30 en bloc kidney transplants from very small DCD donors have been reported in the literature. [8] [9] [10] [11] [12] The lack of published evidence coupled with our substantial programmatic experience with those grafts led us to ask the question to what extent, if any, donor DCD status affects outcomes of kidney grafts recovered from donors ≤10 kg. We hypothesized that DCD does not affect short-and longer-term outcomes of en bloc kidney grafts from very small donors as compared to en bloc grafts from DBD donors.
| PATIENTS AND ME THODS

| Study population
Using a retrospective matched-pair cohort study design, we studied all pediatric en bloc kidney transplants at our center from donors DCD donors during that time period, we pair-matched all 65 DCD donors with 65 DBD pediatric en bloc kidney donors (thus leaving 50 DBD donors that were not used for pair-matching). We performed the pair-matching for the following donor and preservation variables: donor weight, terminal donor creatinine, and total cold ischemic time.
The study population (n = 130) of this retrospective matchedpair cohort study included the 65 consecutive recipients of en bloc kidney grafts from DCD donors ≤10 kg, and 65 pair-matched recipients of en bloc kidney grafts from DBD donors ≤10 kg who were transplanted during the same time period. The study was reviewed by the University of California, Davis Institutional Review Board, which considered it exempt.
| Donor selection
There was no absolute lower weight limit for pediatric en bloc DCD and DBD donors. Contraindications to the use of DCD donors included pre-/terminal need for dialysis as well as anuric acute kidney injury. Maximally acceptable time from withdrawal of care to initiation of the aortic flush in DCD donors was 90 minutes. Given the highly variable preimplantation time spans for which DCD and DBD grafts were placed on hypothermic pulsatile machine perfusion, pump parameters (flow, resistance) were generally not used to exclude pediatric en bloc grafts from consideration for transplantation.
| Recipient selection
For pediatric en bloc grafts we selected, when possible, recipients The recipient operation was performed as previously described. 16 Prior to cross-clamping the recipient iliac arterial and venous vessels for the vascular anastomoses, we systemically heparinized the recipients with an intravenous heparin bolus given at 70 U/kg recipient body weight. The ureteral anastomoses were stented when possible; the stents were removed cystoscopically at 4 weeks posttransplant.
| Organ preservation and transplantation
| Postoperative recipient management
All recipients were given acetylsalicylic acid at 81 mg by mouth daily. Standard posttransplant immunosuppression included a 5-day course of intravenous antithymocyte globulin (Thymoglobulin ® ;
Genzyme, Cambridge, MA) at 1.5 mg/kg per day, intravenous methylprednisolone and oral mycophenolate mofetil for induction, followed by steroid-free maintenance with tacrolimus and mycophenolate mofetil.
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| Data analysis
Delayed graft function (DGF) was defined as the need for at least 1 dialysis session during the first 7 days posttransplant. Graft loss was defined as return to permanent dialysis or death. The estimated GFR (eGFR) was calculated as described by Levey et al.
17
Continuous variables were visually displayed by using box-andwhisker plots, with the whiskers representing the minimum and maximum values (excluding outlier values). 18 We 
| RE SULTS
| Donor, graft, and preservation characteristics
Median donor weight was 5.0 kg and median terminal donor serum creatinine was 0.3 mg/dL for both groups (P = n.s.). Nearly all DCD and DBD grafts had been imported from outside our OPO's DSA (Table 1) .
Median total preservation time was not significantly different for both groups (DCD group, 1444 minutes; DBD group, 1502 minutes) (Table 1 ). With the exception of 2 grafts in the DBD group, all grafts had been preserved on hypothermic pulsatile perfusion after arriving at our Center, with a median machine perfusion time of 540 minutes vs 420 minutes for DCD vs DBD grafts, respectively (P = n.s.). Terminal machine perfusion characteristics (median flow and resistance) were also not significantly different for DCD vs DBD grafts (Table 1) . Additional donor, graft, and preservation characteristics are given in Table 1 .
For the 50 DBD donors/grafts that were not used for pair-matching (and thus excluded from this study), median weight (7.0 kg; range, 4.3 to 10 kg), median terminal creatinine level (0.6 mg/dL; range, 0.1 to 2.76 mg/dL), and median preservation time (1581 minutes; range, 486-3109 minutes) were higher than for the DBD cases (Table 1 , "DBD Group") that had been used for pair-matching with the DCD group.
| Recipient characteristics
The DCD recipient group included significantly more female and older patients ( Table 2 ). All other recipient characteristics, including median weight and BMI, were not significantly different between both groups (Table 2 ).
| Posttransplant complications
Incidence of thrombotic events (affecting either 1, or both, of the grafts' kidneys) was not significantly different for DCD vs DBD grafts ( Table 3) . Rates of ureteral complications (defined as early and late ureteral obstruction, leak, or stricture) were not significantly different between both groups (Table 3) .
| Graft and patient outcomes
We observed a higher DGF rate for recipients of grafts from DCD (vs DBD) donors (25% vs 14%, respectively; P = .7) ( Table 3) .
With a median follow-up time of 4.4 years (DCD group) and 4.9 years (DBD group), we observed 22 graft losses (15, DCD; 7, DBD; P = .1) ( Table 3 ). In the DCD group, the observed graft losses included 4 late losses (>3 years posttransplant) (2 from recurrence of primary disease, 1 from rejection, and 1 from a surgical complication) ( not significantly different between both groups (Table 3) . At 1 year, death-censored graft survival was 89% for DCD and 91% for DBD graft recipients; at 5 years, graft survival was 87% and 91%, respectively (P = .
3) (Figure 1 ).
Renal function (as measured by median eGFR) between 1 month and 6 years posttransplant was significantly lower for DCD (vs DBD)
grafts at 1 month (22 vs 27 mL/min per 1.73 m 2 ; P = .002) and at 3 months (38 vs 48 mL/min/1.73 m 2 ; P = .004), but not thereafter (Figure 2) .
At 1 year, patient survival was 99% for DCD and DBD graft recipients; at 5 years, patient survival was 90% vs 97%, respectively (P = .16).
| D ISCUSS I ON
Despite the significant potential for organ DCD by small children, recovery and transplantation of small pediatric DCD donor kidneys remain uncommon. (because of the very low absolute number of DCD cases). 4, 6, 20 This lack of published evidence prompted us to review our significant experience with kidney transplants from very small DCD donors. We focused our analysis on DCD donors whose kidneys had to be transplanted en bloc due to a donor size of ≤10 kg, and compared them to outcomes of contemporaneous transplants from similarly sized DBD en bloc kidney donors. In order to adjust for baseline risk factors that might impact outcomes, we pair-matched the DCD grafts with DBD grafts (1) for donor size (weight) and preservation time (both have previously been identified as risk factors for pediatric donor kidney graft loss) and (2) for terminal donor creatinine in order to allow for more adequate analysis of early posttransplant graft function. 3, 4, 21 The pair-matched study and control cohorts did not demonstrate any significant differences with respect to baseline donor demographic and preservation characteristics.
Importantly, we observed that DCD as compared to DBD grafts had similar early graft loss rates from thrombosis and PNF. Moreover, longer-term (up to 5 years) graft function and graft survival were not statistically significantly different. In both groups, graft losses followed a characteristic pattern of a similar-relatively sizeableproportion of early graft losses from thrombosis and PNF, followed by stable longer-term function. We noted more graft losses in the DCD (vs the DBD) group; this difference was mostly attributable to the higher rates of death with a functioning graft and of recurrent disease in the DCD group. The higher rate of death with a functioning graft in the DCD group was not readily attributable to a (premature) decline in graft function (Table 3) . We thus speculate that the higher rates of death with a functioning graft for DCD recipients may at least in part be related to that recipient group's higher median age and higher proportion of diabetics. Similarly, the higher number of graft losses due to recurrent disease in the DCD group is most likely not causally related to their donors' DCD status but reflects rather our inability The present study is the first larger (single-center or registry)
analysis suggesting that DCD status of pediatric kidney donors does not confer an increased risk for PNF and early or late graft loss. In contrast, a large Dutch registry analysis of transplants from pediatric DCD (vs DBD) donors had suggested increased PNF and graft loss rates for those transplants. 7 The multicentric nature and the very long study period (1981 to 2006) of that registry analysis render analysis of the potential reasons for the differing outcomes between the present and the Dutch study challenging, if not impossible. 7 By contrast, our results suggest that DCD does not appear to constitute an independent risk factor for kidney graft loss in the current era for DCD kidneys from very small donors. We speculate that the lack of cellular senescence in these very young donor kidneys is a major contributory factor to the observed lack of long-term eGFR decline in recipients of DCD and DBD en bloc donor kidneys (even though . 6 In our study, rates of vascular thrombotic events and of ureteral complications were similar for DCD and DBD grafts.
We were not able to determine why DCD recovery did not appear to exert any adverse effect on technical-surgical graft outcomes in our experience. We speculate that accurate identification of any recovery injuries (by direct graft inspection during back-table preparation and during machine perfusion), repair of these if appropriate, and discard of the graft if necessary, may all have contributed to our observed equivalent outcomes of kidney transplants from DCD and DBD donors. 13, 16 Our results suggest therefore that the overall high nonrecovery and discard rates reported for these DCD organs might not be entirely warranted. 3, 4, 22 Further study and education of the transplant community may be necessary to allow these donors in the future to contribute more significantly to the deceased donor pool.
Short-term graft outcomes in both cohorts are in line with findings in published Scientific Registry of Transplant Recipients analyses for donors <8 kg. 3, 4 We believe that the absence of longterm decline of graft function and excellent functional and deathcensored graft survival of these kidneys (from both DCD and DBD donors) warrant careful counseling of the potential recipients of these grafts with respect to balancing the increased short-term graft loss risk vs the benefit of excellent long-term graft function and survival. Furthermore, outcome parameters currently used for regulatory purposes in the United States are heavily focused on short-term outcomes (eg, graft and patient survival at 1 year posttransplant); these warrant further discussion and public debate in order to maximize transplant opportunities and number of recipient life years spent with a functioning graft.
Our study is subject to the limitations of any retrospective analysis, in spite of the pair-matching and lack of significant differences between study and control cohort at baseline. In particular, donor selection based on other medical and surgical criteria might have affected our results in 1 or in both groups. For instance, there was a very low proportion of donors with acute kidney injury in the DCD (and hence also the DBD control cohort) (data not shown), thus limiting extrapolation of our results to all donors across the entire spectrum of terminal donor kidney function. Also, as discussed above, thorough, and for the purposes of this study nonquantifiable, surgical inspection and selection of the grafts during the back-table preparation and machine perfusion phases were possibly contributing factors with respect to the minimization of technical graft losses following DCD recovery. Furthermore, since virtually all grafts had been placed on machine perfusion prior to implantation, our analysis was not able to discern the potential contribution of machine perfusion to our short-and long-term outcomes. 23 Finally, our study is also limited by the fact that the vast majority of the grafts in both groups had been imported and that our median cold ischemic time was therefore greater than 28 hours. We were thus unable to determine whether shorter preservation times might have beneficially affected short-term outcomes (eg, graft thrombosis, PNF) and long-term outcomes. 21 We conclude that DCD status is associated with slower early graft function as measured by eGFR, but does not appear to con- 
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